Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.

Document Type

Article

Publication Date

11-22-2022

Publication Title

JAMA

Abstract

This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.

Volume

328

Issue

20

First Page

2062

Last Page

2064

DOI

10.1001/jama.2022.16476

ISSN

1538-3598

PubMed ID

36260754

Share

COinS